I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Eli Lilly (LLY) stock gains as the company's next-generation weight loss candidate, retatrutide succeeds in a Phase 3 trial.

Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in ...